Stone Point Capital Closes Tenth Flagship Fund with $11.5 Billion of Committed Capital
GREENWICH, Conn. — Stone Point Capital LLC, a private equity firm focused on financial services and related industries, today announced the final closing of its tenth private equity fund, Trident X, with $11.5 billion in total commitments. Trident X exceeded its original target and hard cap of $9 billion and is approximately $2.5 billion larger than Trident IX, a $9 billion fund, which closed in 2022.
Article content
Trident X received strong support from its existing investor base, as well as first-time commitments from a number of leading institutional investors globally. General Partner and affiliated entities contributed approximately $750 million.
'We are grateful to our limited partners for their continued trust and support, and we are proud of the enduring strength of our Trident Funds over 30 years and many market cycles,' said Chuck Davis, Chairman and Co-Chief Executive Officer of Stone Point Capital. 'With Trident X, we will continue doing what we believe we do best – proactively identifying exceptional owner-operators in and around the global financial services industry and helping them build lasting value in their businesses.'
Article content
Jim Carey, Co-Chief Executive Officer of Stone Point Capital, added, 'We believe the consistency of our team, strategy and results continues to give us a distinct advantage in sourcing investments through our extensive network. We are excited by the opportunities we see for our tenth flagship fund and remain focused on creating value for our investors.'
Article content
Trident X began its investment period in May 2025 and has closed on one investment to date – Ultimus Fund Solutions, a provider of full-service fund administration services.
Article content
Stone Point has over 30 years of experience investing in the global financial services industry, beginning with private equity investments in insurance underwriting and expanding over time into a wide range of financial and business services sectors. Members of the senior leadership team have led operations since 1998. The Firm partners with experienced management teams and is flexible with respect to the types of transactions pursued through its Trident Funds. Stone Point has experience in standalone structured buyouts, as well as in carve-outs from larger organizations – bringing deep sector knowledge and an expansive network to every portfolio company engagement. Stone Point has invested in more than 160 companies across 10 active verticals and over 70 sub-sectors. The firm also has a credit-investing platform, Stone Point Credit, which has nearly $10 billion of assets under management.
Article content
Debevoise & Plimpton LLP acted as legal counsel for Stone Point in connection with the formation of Trident X.
Article content
About Stone Point Capital
Article content
Stone Point is an investment firm with more than $65 billion of assets under management across its private equity and credit platforms. Stone Point targets investments in companies in the global financial services industry and related sectors based primarily in North America and Western Europe. The firm invests in alternative asset classes, including private equity through its flagship Trident Funds and credit through commingled funds and separately managed accounts. In addition, Stone Point Capital Markets supports its firm, portfolio companies and other clients by providing dedicated financing solutions. For more information, please visit www.stonepoint.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts
Article content
Article content
Prosek Partners
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
a minute ago
- National Post
Bragg Gaming to Release Second Quarter 2025 Results on August 14
Article content TORONTO — Bragg Gaming Group ( NASDAQ: BRAG, TSX: BRAG) (' Bragg ' or the ' Company ') today confirmed that it will release its second quarter 2025 financial results prior to the opening of the financial markets on Thursday, August 14, 2025. The release will be followed by a conference call at 8:30 a.m. Eastern Time, hosted by Bragg Chief Executive Officer, Matevž Mazij and Chief Financial Officer, Robbie Bressler, to discuss the Company's financial results and provide a business update. During the call, management will review a presentation that will be available on the day of the call and can be accessed at: To join the call, please use the below dial-in information: Article content Article content Article content Article content Canada – Toronto +1-647-495-7514 Article content Article content Article content Article content Conference ID: 3967732 Article content A webcast of the call and presentation may also be viewed at: An audio recording of the Event will be available via the Echo Replay platform until August 21, 2025. To access the platform by phone, please dial-in using one of the numbers listed below and input Playback ID: 3967732 followed by # key: Article content USA/ Canada Toll-Free: +1(800) 770-2030 USA Toll: +1(609) 800-9909 Canada Toll: +1(647) 362-9199 United Kingdom: +44 203 433 3849 Article content About Bragg Gaming Group Article content Bragg Gaming Group Article content ( Article content , Article content TSX: BRAG Article content ) is an iGaming content and platform technology solutions provider serving online and land-based gaming operators with its proprietary and exclusive content, and cutting-edge player account management ('PAM') technology. Bragg Studios offer high-performing and passionately crafted casino game titles using the latest in data-driven insights from in-house brands including Wild Streak Gaming, Atomic Slot Lab and Indigo Magic. Its proprietary content portfolio is complemented by a selection of exclusive titles from carefully selected studio partners under the Powered By Bragg program. Games built on Bragg's remote games server ('RGS') technology are distributed via the Bragg HUB content delivery platform and are available exclusively to Bragg customers. Bragg's powerful, modular PAM technology powers multiple leading iCasino and sportsbook brands and is supported by expert in-house managed, operational, and marketing services. Content delivered via the Bragg HUB either exclusively or from the Bragg aggregated games portfolio is managed from a single back-office which is supported by a cutting-edge data platform, and Bragg's award-winning Fuze™ player engagement toolset. Bragg is licensed, certified, or otherwise approved and operational in over 30 regulated iCasino markets globally, including in the U.S., Canada, LatAm and Europe. Article content Article content LinkedIn Article content Article content Article content Article content Article content Article content
Globe and Mail
a minute ago
- Globe and Mail
Union Pacific, now the subject of merger talks, reports second quarter profit of $1.8 billion
Union Pacific reported Thursday that its adjusted profit grew to $1.8 billion in the second quarter as merger rumors to swirl around the nation's largest railroad. The Omaha, Nebraska, per-share earnings rose rose to $3.03, beating Wall Street expectations and easily topping the $2.71 per-share profit it reported in the same period last year. Analysts were expecting profit of $2.91 per share for the recent quarter. Operating revenue grew 2% over last year, to $6.2 billion, the company said. Sources told The Associated Press last week that Union Pacific and Norfolk Southern are in merger talks that would create the a railroad in North America that essentially connects the East and West Coasts.
National Post
a minute ago
- National Post
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Article content BRISBANE, Calif. — Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company ('Lilly') to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate's molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-to-drug proteins, bringing forth medicines with a new mechanism of action for diseases of high unmet medical need. Article content 'This collaboration fuels our vision to make molecular gates into medicines,' said Jordi Mata-Fink, Ph.D., co-founder and CEO of Gate. 'Our drugs eliminate disease-causing proteins at their source with a convenient pill. Lilly's expertise in developing innovative therapeutics to address unmet medical needs for the benefit of patients stands apart. Lilly is an ideal partner for Gate as we develop the first wave of molecular gate drugs.' Article content Under the terms of the agreement, Gate will receive an upfront payment and equity investment, will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales. Gate can also receive certain preclinical R&D support from Lilly ExploR&D, a pillar of Lilly Catalyze360, for their internal programs. Article content 'Lilly has shown its commitment to building the biotech ecosystem through win-win partnerships with innovative start-up companies,' said Vineeta Agarwala, M.D., Ph.D., board member at Gate and general partner at a16z Bio + Health. 'With this collaboration, Lilly gains access to a transformative new drug modality and Gate taps into Lilly's deep expertise in delivering meaningful therapeutics. Ultimately, patients will be the big winners.' Article content About Gate Bioscience Article content Gate Bioscience is creating a new class of medicines called molecular gates, small molecules that eliminate a disease-causing secreted or membrane protein at its source. Secreted and membrane proteins pass through a common channel in the cell before they are secreted into the body. Molecular Gates recognize and block a specific protein from crossing the channel, causing it to be degraded by the cell instead of being secreted. By eliminating the harmful protein at its source, Gate aims to eliminate the disease for patients. Founded in 2021, Gate is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at Article content Article content Article content Article content
